Desensitization of vascular response in vivo: Contribution of genetic variation in the α2B-adrenergic receptor subtype

Journal of Hypertension

Volumn 28, Issue 2, 2010, Pages 278-284

  Muszkat, Mordechai ^a,d   Kurnik, Daniel ^a   Sofowora, Gbenga G ^a   Solus, Joseph ^b   Xie, Hong Guang ^a   Harris, Paul A ^c   Williams, Scott M ^b   Wood, Alastair J J ^a   Stein, C Michael ^a  

^a Division of Clinical Pharmacology   (United States)

^b Division of Human Genomics   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Adrenergic a; Adrenergic receptor agonists; Genetic variability; Human; Receptor desensitization; Receptor vasoconstriction

Indexed keywords

ALPHA 2B ADRENERGIC RECEPTOR; DEXMEDETOMIDINE;

3' UNTRANSLATED REGION; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DESENSITIZATION; DORSAL HAND VEIN; DRUG INFUSION; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAND; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; VASCULAR RESISTANCE; VASOCONSTRICTION; VEIN;

EID: 75149158497     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328333d212     Document Type: Article

References (28)

1. 2 adrenoceptors. Eur J Pharmacol 1998; 361:1-15.
2. Dinenno FA, Eisenach JH, Dietz NM, Joyner MJ. Postjunctional alpha-adrenoceptors and basal limb vascular tone in healthy men. J Physiol 2002; 540 (Pt 3):1103-1110.
3. Baumgart D, Haude M, Gorge G, Liu F, Ge J, Grosse-Eggebrecht C, et al. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation 1999; 99:2090-2097.
4. Talke P, Stapelfeldt C, Lobo E, Brown R, Scheinin M, Snapir A. Effect of alpha2B-adrenoceptor polymorphism on peripheral vasoconstriction in healthy volunteers. Anesthesiology 2005; 102:536-542.
5. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology 1992; 77:1134-1142.
6. Muszkat M, Sofowora GG, Wood AJ, Stein CM. Alpha2-adrenergic receptor-induced vascular constriction in blacks and whites. Hypertension 2004; 43:31-35.
7. 2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999; 402:181-184.
8. 2-adrenergic receptor subtypes b and c. Science 1996; 273:803-805.
9. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 1996; 273:801-803.
10. Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001; 53:319-356.
11. Chotani MA, Mitra S,Su BY, FlavahanS, Eid AH, Clark KR, et al. Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004; 286:H59-H67.
12. Brunton LL, Lazo JS, Parker KL, editors. Goodman's & Gilman's. The pharmacological basis of therapeutics, 11th ed. Columbus, Ohio, USA: McGraw-Hill, chapter 1. pp. 31-32.
13. Jewell-Motz EA, Liggett SB. An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required for agonist-promoted phosphorylation and desensitization. Biochemistry 1995; 34:11946-11953.
14. Eason MG, Liggett SB. Subtype-selective desensitization of alpha 2-adrenergic receptors. Different mechanisms control short and long term agonist-promoted desensitization of alpha 2C10, alpha 2C4, and alpha 2C2. J Biol Chem 1992; 267:25473-25479.
15. Daunt DA, Hurt C, Hein L, Kallio J, Feng F, Kobilka BK. Subtype-specific intracellular trafficking of alpha2-adrenergic receptors. Mol Pharmacol 1997; 51:711-720.
16. 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J Biol Chem 2001; 276:4617-4922.
17. 2 adrenergic receptor response. Pharmacogenet Genomics 2005; 15:23-28.
18. 2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenet Genomics 2005; 15:407-414.
19. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins: 2. Br J Clin Pharmacol 1994; 38:289-305.
20. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins: 1. Br J Clin Pharmacol 1994; 38:181-196.
21. 2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol 2001; 37:1516-1522.
22. 2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. J Am Coll Cardiol 2003; 41:190-194.
23. Heinonen P, Jartti L, Jarvisalo MJ, Pesonen U, Kaprios JA, Ronnemaa T, et al. Deletion polymorphism in the alpha2B-adrenergic receptor gene is associated with flow-mediated dilatation of the brachial artery. Clin Sci 2002; 103:517-524.
24. 2-adrenoceptors on haemodynamic responses to adrenaline. Clin Sci 2003; 104:509-520.
25. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345:1030-1035.
26. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol 1988; 150:9-14.
27. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, et al. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 1999; 56:154-161.
28. Schindler C, Grossmann M, Dobrev D, Francke K, Ravens U, Kirch W. Reproducibility of dorsal hand vein responses to phenylephrine and prostaglandin F2 alpha using the dorsal hand vein compliance method. J Clin Pharmacol 2003; 43:228-236.